


Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care

Gerald Pierone¹, Laurence Brunet², Jennifer S Fusco², Cassidy Henegar³, Supriya Sarkar³, Jean van Wyk⁴, Vani Vannappagari³, Gregory P Fusco²
¹ Whole Family Health Center, Vero Beach, FL, USA; ² Epividian, Durham, NC, USA; ³ ViiV Healthcare, Research Triangle Park, NC, USA; ⁴ ViiV Healthcare, Brentford, UK



Background

- Dolutegravir/lamivudine (DTG/3TC) is the second two-drug regimen approved in the US for the treatment of people with HIV (PWH)
- On 08Apr2019, the FDA expanded the indication for DTG/3TC to include ART-experienced, suppressed individuals
- DTG/3TC is indicated for
 - PWH without any known substitutions associated with resistance to the individual components
 - PWH without hepatitis B co-infection

Objective

To describe the real-world experience of virologically suppressed, ART experienced adults switching to DTG/3TC from one of three commonly prescribed traditional three-drug regimens in the US

Methods

Data Source: OPERA Cohort

- Prospectively captured, routine clinical data from electronic health records from 84 clinics in 18 US states/territories
- ~12% of people with HIV in US

Inclusion Criteria

- HIV-1 positive
- ≥13 years old
- Switch to DTG/3TC between 8APR2019 and 30APR2021
- Switched from bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC), DTG/abacavir (ABC)/3TC or DTG+TAF/FTC
- Viral load <50 copies/ml at switch
- No known history of virologic failure or resistance

Censoring Criteria

- Any change in DTG+3TC regimen (add or remove of any antiretroviral)
- Lost to follow-up (18 months after last visit, lab, or clinic contact)
- Death
- Study end (31OCT2021)

Definitions

- Baseline: date of the first DTG/3TC prescription)
- Discontinuation:
 - Switch from DTG/3TC to any other regimen (e.g., stop DTG or 3TC, and/or add another core agent or nucleoside reverse transcriptase inhibitor)
 - ART interruption
- Loss of suppression
 - First VL ≥50 copies/mL
 - First VL ≥200 copies/mL
- Confirmed virologic failure: 2 VL ≥ 200 copies/mL or discontinuation after 1 VL ≥ 200 copies/mL

Statistical Analyses

- Incidence rates assessed with univariate Poisson regression
 - Overall
 - Stratified by age, sex and race

Results

Table 1. Population characteristics at ART initiation

	Overall N = 787
Age, median years (IQR)	44 (33, 55)
Ryan White/ADAP program beneficiary, n (%)	252 (32)
CD4 cell count, median cells/μL (IQR)	738 (569, 932)
History of AIDS, n (%)	149 (19)
HBV co-infection, n (%)	19 (2)
Any comorbidity ^a actively managed in past 12 months, n (%)	422 (54)
Prior ART regimen, n (%)	
DTG/ABC/3TC	421 (54)
BIC/TAF/FTC	240 (30)
DTG + TAF/FTC	126 (16)

3TC, lamivudine; ABC, abacavir; BIC, bictegravir; DTG, dolutegravir; FTC, emtricitabine; IQR, interquartile range; TAF, tenofovir alafenamide

^a Autoimmune Disease, Cardiovascular Disease, Invasive Cancers, Endocrine Disorders, Mental Health Disorders, Liver Disease, Bone Disorders, Peripheral Neuropathy, Renal Disease, Hypertension, Substance Abuse, COVID-19

Table 2. Duration of follow-up and confirmed virologic failure, stratified by age, sex and race

	N	Months of follow-up, Median (IQR)	Confirmed virologic failure ^a , n	Confirmed virologic failure, IR per 100 py (95% CI)
Overall	787	13.6 (8.2, 22.3)	≤5	0.43 (0.16, 1.00)
Age < 50	490	13.7 (8.8, 22.2)	≤5	0.52 (0.17, 2.00)
Age ≥ 50	297	13.5 (7.5, 22.3)	≤5	0.29 (0.04, 2.00)
Male	659	13.6 (8.3, 22.4)	≤5	0.51 (0.19, 1.00)
Female	128	13.6 (7.6, 21.3)	0	0
Black	250	13.3 (7.9, 21.3)	≤5	1.07 (0.35, 3.00)
Non-Black	537	13.3 (7.9, 21.3)	≤5	0.15 (0.02, 1.00)

CI, confidence interval; IR, incidence rate; py, person-years

^a Masking of cells with 1 to 5 individuals is required by HIPAA (US federal law to protect sensitive patient health information)

Table 3. Reasons for discontinuation^a among discontinuers

	Discontinuers N = 170
Treatment-related reasons, n (%) (i.e., detectable VL, adverse diagnosis/side effect, lab abnormality), n (%)	6 (4)
Any other reason, n (%) (i.e., simplification, access issues, non-adherence, therapeutic gap, patient preference, provider preference)	66 (39)
None identified, n (%)	101 (59)

^a Reasons are not mutually exclusive

Figure 1. Incidence rates of DTG/3TC discontinuation, stratified by age, sex and race




Figure 2. Incidence rates of loss of suppression (first VL ≥50 copies/mL) among individuals with ≥1 follow-up VL, stratified by age, sex and race





Figure 3. Incidence rates of loss of suppression (first VL ≥200 copies/mL) among individuals with ≥1 follow-up VL, stratified by age, sex and race



Discussion

- Among virally suppressed adults, switching to DTG/3TC was observed to be:
 - Virologically effective, with low rates of loss of viral suppression (≥200 copies/mL) and rare virologic failure events
 - Well tolerated, with few discontinuations linked to treatment-related events
 - The absence of differences across strata of age, sex and race suggests that all groups were able to take DTG/3TC with equal success
 - Generalizability is limited by the narrow inclusion criteria
- Presented at AIDS 2022 – The 24th International AIDS Conference

Key Findings

DTG/3TC was observed to be an effective and well tolerated treatment option among virologically undetectable ART-experienced PWH

Acknowledgements

This research would not be possible without the generosity of people living with HIV and their OPERA® caregivers. Additionally, we are grateful for the following individuals: Lito Torres (SAS programming), Robin Beckerman (QA), Bernie Stooks and Lisa Lutz (Database Mgmt), and Judy Johnson (Medication Terminology Classification).

Support

ViiV Healthcare



This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.